期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

DNA异常甲基化在卵巢癌中的研究进展 被引量：2

Research Progress of DNA Abnormal Methylation in Ovarian Cancer
下载PDF
导出
摘要 卵巢癌是死亡率最高的妇科恶性肿瘤,严重威胁着女性的生命健康,其发生与多种分子变化有关。表观遗传学改变与人类多种肿瘤有着密切的关系,而肿瘤抑制基因的DNA甲基化则是卵巢癌中常见的表观遗传学现象,与卵巢癌的发生、发展有着密切的联系。DNA甲基化属于基因表观遗传调控的重要方式之一。新的研究发现,DNA异常甲基化,尤其是基因启动子CpG岛高甲基化,使肿瘤抑制基因——乳腺癌易感基因1(BRCA1)、Ras相关区域1A基因(RASSF1A)等失活,在卵巢癌发生、发展中起重要作用。综述DNA异常甲基化在卵巢癌中的研究进展,可为卵巢癌发病机制、早期诊断、治疗及判断预后提供新的方法。 Ovarian cancer, the most lethal gynecological cancer,is a serious threat to women＇s health and lives. Various molecular changes have been identified in ovarian cancer. The change of epigeneties is closely related with the carcinogensis in human and tumor suppressor gene DNA methylation is a common phenomenon in ovarian cancer. DNA methylation is one of the main way of epigenetie mechanisms of transcription control. The new reports indicate that aberrant expression of genes result from abnormal DNA methylation of specific genes and an important effect with the carcinogenesis and development of ovarian cancer. Especially the hypermethylation of CpG island in the promoter region may contribute to the loss of tumor suppressor genes such as BRCA1 and RASSF1A so on.We summarized the research progress of DNA abnormal methylation in ovarian cancer, which would be helpful to the molecular mechanisms in early diagnosis, therapy and prognosis of ovarian cancer.
作者 高桂芹 林琬君
机构地区 天津市中心妇产科医院
出处 《国际妇产科学杂志》 CAS 2013年第1期61-63,共3页 Journal of International Obstetrics and Gynecology
关键词 卵巢肿瘤 DNA甲基化 基因 肿瘤抑制 基因 BRCA1 ras蛋白质 Ovarian neoplasms DNA methylation Genes, tumor suppressor Genes, BRCA1 ras proteins
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Jemal A,Siegel R,Ward E,et al. Cancer statistics,2009 [J]. CA Cancer J Clin, 2009.59 (4) : 225-249.
  • 2Esteller M. Epigenetics in cancer [J]. N Engl J Med,2008,358 (11) : 1148-1159.
  • 3Metivier R ,C.allais R ,Tiffoche C ,et al, Cyclical DNA methylation of a transcriptionally active promoter [ J ]. Nature , 2008,452 ( 7183 ) : 45-50.
  • 4Asadollahi R, Hyde AC, Zhong XY. Epigenetics of ovarian cancer: from the lab to the clinic [J]. Gynecol 0ncol,2010,118 (1):81-87.
  • 5Su HY, Lai HC, Lin YW, et al. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer [J]. Int J Cancer, 2009,124 (2) : 387-393.
  • 6Michaelson R, Keshet I, Straussman R,et al. Genome-wide de novo methylation in epithelial ovarian cancer [J~. Int J Gynecol Cancer , 2011,21 (2) : 269-279.
  • 7Watts GS, Futscher BW, Hohan N,et all. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage[J]. BMC Med Genomics ,2008,1:47.
  • 8Chaudhry P,Srinivasan R, Patel FD. Utility of gene promoter methy- lation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer[ J ]. Cancer Invest, 2009,27 (8) : 877-884.
  • 9刘洋,胡越,凌志强.肿瘤抑制基因DNA甲基化与宫颈癌研究进展[J].国际妇产科学杂志,2010,37(5):322-324. 被引量：6
  • 10Ma L,Guo Q ,Ma Y ,et al. Clinicopathological implications of inac- tivation of RASSF1A in serous epithelial ovarian cancer[J]. Eur J Gynaecol Onco1,2009,30(4) :370-374.

二级参考文献20

  • 1Munoz N.Human papillomavirus and cancer:the epidemiological evidence[J].J Clin Virol,2000,19(1/2):1-5.
  • 2Park SY,Kim BH,Kim JH,et al.Methylation profiles of CpG island loci in major types of human cancers[J].J Korean Med Sci,2007,22(2):311-317.
  • 3Henken FE,Wilting SM,Overmeer RM,et al.Sequential gene promoter methylation during HPV-induced cervical carcinogenesis[J].Br J Cancer,2007,97(10):1457-1464.
  • 4Wentzensen N,Sherman ME,Schiffman M,et al.Utility of methylation markers in cervical cancer early detection:appraisal of the state-of-the-science[J].Gynecol Oncol,2009,112(2):293-299.
  • 5Flatley JE,McNeir K,Balasubramani L,et al.Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis[J].Cancer Epidemiol Biomarkers Prey,2009,18(10):2782-2789.
  • 6Kim JH,Choi YD,Lee JS,et al.Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens[J].Gynecol Oncol,2010,116(1):99-104.
  • 7Goncalves MA,Le Discorde M,Simoes RT,et al.Classical and nonclassical HLA molecules and p16 (INK4a)expression in precursors lesions and invasive cervical cancer[J].Eur J Obstet Gynecol Reprod Biol,2008,141(1):70-74.
  • 8Kang S,Kim J,Kim HB,et al.Methylation of p16INK4a is a nonrare event in cervical intraepithelial neoplasia[J].Diagn Mol Pathol,2006,15(2):74-82.
  • 9Nehls K,Vinokurova S,Schmidt D,et al.p16 methylation does not affect protein expression in cervical carcinogenesis[J].Eur J Cancer,2008,44(16):2496-2505.
  • 10Overmeer RM,Henken FE,Snijders PJ,et al.Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC[J].J Pathol,2008,215(4):388-397.

共引文献5

同被引文献37

  • 1Fasching PA, Gayther S, Pearce L, et al. Role of genetic pol- ymorphisms and ovarian cancer susceptibility [J] . Mol On- col, 2009, 3 (2): 171-181.
  • 2Swenberg JA, Lu K, Benjamin C, et al. Endogenous versus exogenous DNA adducts: their role in carcinogenesis epidemi- ology, and risk assessment [J] . Toxicol Sci, 2011, 120 ( Suppl 1 ) : S130 - S145.
  • 3Metivier R, Gallais R, Tiffoche C, et al. Cyclical DNA meth- ylation of a transcriptionally active promoter [ J ] . Nature, 2008, 452 (7183): 45-50.
  • 4Asadollahi R, Hyde AC, Zhong XY. Epigenetics of ovarian cancer: from the lab to the clinic [J] . Gynecol Oncol, 2010, 118 (1): 81-87.
  • 5Mchaelson R, Keshet I, Straussman R, et al. Genome - wide denovo methylation in epithelial ovarian cancer [J] . Int J Gy- necol Cancer, 2011, 21 (2): 269-279.
  • 6Watts GS, Futscher BW, Holtan N, et al. DNA methylation changes in ovarian cancer are cumulative with disease progres- sion and identify tumor stage [J] . BMC Med Genomics, 2008, 1 (1): 47.
  • 7Chaudhry P, Srinivasan R, Patel FD. Utility of gene promoter methylation in prediction of response to platinum - based chem- otherapy in epithelial ovarian cancer [ J ] . Cancer Invest, 2009, 27 (8): 877-884.
  • 8Ma L, Guo Q, Ma Y, et al. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancer [J] . Eur J Gynaecol Oncol, 2009, 30 (4) : 370 -374.
  • 9Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer [J] . Dis Markers, 2007, 23 (1/ 2) : 73 -87.
  • 10Kimura S, Naganuma S, Susuki D, et al. Expression of mi- croRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR- 205 and miR- 21 are specific markers for HNSCC and ESCC [J] . Oneol Rep, 2010, 23 (6) : 1625 - 1633.

引证文献2

二级引证文献4

国际妇产科学杂志
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部